The CBM Drug Portfolio

The CBM drug portfolio contains patented technology focused on the
treatment of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and pancreatic cancer.

KPC-34 Developed at Wake Forest School of Medicine

Background
70% of All AML patients are over the age of 60 and only 6.6% of patients are still alive 5 years after diagnosis. Gemcitabine and Cytarabine are the backbone of AML and ALL therapy, but life expectancy is poor and relapses are much harder to treat.

Cytarabine (Ara-C) has been a major drug for acute myeloid leukemia (AML) treatment for more than three decades. But KPC34 has shown superior results when tested against Cytarabine.

KPC34 is superior to Cytarabine

Median Survival

  • PBS 23
  • Ara-C 25
  • KPC34 44.5

p=0.0007****

KPC34, when combined with Doxorubicin, has shown better results than Ara-C

KPC34 + Dox is More Effective than Ara-C + Dox in Treatment of Naïve ALL In Vivo

Median Survival

  • PBS 14.5
  • Ara-C + Dox 30.5
  • KPC34 + Dox 50.5

Log-rank test p < 0.0001****

KPC34 has also shown superior results when tested against Gemcitabine

KPC34 is superior to Gemcitabine

In preclinical data, KPC has also shown to be active against human ALL

KPC34 is active against human ALL

KPC34 has also shown superior results in treating mice after a relapse

Retreating mice with KPC34 after relapse

KPC34 has also shown superior results in treating mice after a relapse

Repeat dosing improves survival

Median Survival

  • PBS 22.5
  • KPC34 44.5
  • KPC34 re-treat 78.5

p=0.0001****

KPC34 Vs. re-treat=0.0028**